“Humana’s stock trades at a 7.8% discount to the average analyst price target of $299, following a 4.7% one-year return and 33.6% five-year return, with ongoing margin pressures in Medicare Advantage impacting valuation metrics like a trailing P/E of 25.9 and forward P/E of 21.1.”
Humana, a leading health insurance provider focused on Medicare Advantage plans, currently trades at $276.85 per share, reflecting a market capitalization of $33.3 billion. This price positions the stock at a notable discount to consensus analyst targets, amid shareholder returns that have varied across time horizons. The enterprise value stands at $40.5 billion, incorporating debt and cash positions that highlight the company’s operational scale in the healthcare sector.
Shareholder Returns Analysis Over the past year, Humana delivered a total shareholder return of 4.7%, underperforming broader market benchmarks amid industry headwinds such as rising medical costs and regulatory shifts. In contrast, the five-year return reaches 33.6%, benefiting from earlier expansions in membership and premium revenues. Year-to-date performance shows an 8.1% gain, driven by partial recovery in stock price following dips tied to margin concerns. Three-year returns are stronger at 40.6%, underscoring resilience in core business lines despite volatility.
These mixed outcomes stem from fluctuating profitability in key segments. Medicare Advantage, which accounts for the bulk of revenues, has faced elevated utilization rates post-pandemic, compressing margins. Investors have seen dividend support, with a forward yield of 1.3% and annual payout of $3.54 per share, providing some stability amid price fluctuations.
Valuation Metrics Humana’s current valuation incorporates traditional ratios that suggest a blend of growth potential and risk. The trailing price-to-earnings ratio is 25.9, based on earnings per share of $10.69 over the last twelve months. Forward P/E drops to 21.1, anticipating earnings growth despite near-term challenges. Beta of 0.46 indicates lower volatility relative to the market, appealing to conservative investors.
| Metric | Value |
|---|---|
| Trailing P/E | 25.9 |
| Forward P/E | 21.1 |
| Price-to-Sales | 0.26 |
| Price-to-Book | 1.8 |
| Enterprise Value/EBITDA | Not Applicable |
| Beta | 0.46 |
| Dividend Yield | 1.3% |
The stock’s 52-week range spans $206.87 to $315.35, with current trading near the lower end, amplifying perceptions of undervaluation. Free cash flow of approximately $1.6 billion supports ongoing investments in primary care and pharmacy services.
Analyst Perspectives and Targets Analysts maintain a mixed stance, with a consensus rating leaning toward Hold. The average price target is $299, implying an upside of about 7.8% from current levels. Targets range from a low of $250, reflecting pessimism over persistent margin erosion, to a high of $353, betting on successful cost controls and membership growth. Number of analysts covering the stock exceeds 20, with roughly equal splits between Buy and Hold recommendations, and fewer Sells.
Earnings estimates project $17.07 per share for the current fiscal year, declining to $12.21 in the next due to expected pressures in benefit ratios. Revenue forecasts point to $129.2 billion this year, rising to $145.3 billion next, driven by premium increases and expansion in Medicaid and group plans.
Key Risks and Opportunities Margin headwinds persist, with medical loss ratios elevated due to higher inpatient admissions and outpatient services. Regulatory risks in Medicare Advantage, including star rating adjustments, could impact reimbursements. On the opportunity side, investments in integrated care models, such as primary care clinics, aim to restore pre-tax margins to 3% or higher. Membership growth in senior-focused plans remains a tailwind, with potential for improved retention through value-based care.
Strategic realignments, including contract renegotiations and operational efficiencies, are expected to mitigate near-term declines. Investors eyeing entry points may view the current discount as attractive, balanced against sector-wide uncertainties in healthcare spending.
Disclaimer: This news report is for informational purposes only and does not constitute financial advice. Sources are various financial data providers.